Wall Street brokerages predict that ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) will announce $1.59 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for ZIOPHARM Oncology’s earnings. The highest sales estimate is $1.70 million and the lowest is $1.46 million. ZIOPHARM Oncology posted sales of $1.60 million in the same quarter last year, which suggests a negative year-over-year growth rate of 0.6%. The firm is scheduled to report its next earnings report on Thursday, February 15th.
According to Zacks, analysts expect that ZIOPHARM Oncology will report full-year sales of $1.59 million for the current fiscal year, with estimates ranging from $6.26 million to $7.00 million. For the next year, analysts anticipate that the firm will report sales of $5.41 million per share, with estimates ranging from $3.00 million to $6.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.66 million. During the same period in the prior year, the firm posted ($0.11) EPS. ZIOPHARM Oncology’s revenue was up .0% on a year-over-year basis.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.38 on Friday. ZIOPHARM Oncology has a fifty-two week low of $3.90 and a fifty-two week high of $7.88.
In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper bought 6,440 shares of the stock in a transaction on Wednesday, November 8th. The stock was purchased at an average price of $4.68 per share, with a total value of $30,139.20. Following the acquisition, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at $5,071,861.08. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 10.40% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. boosted its position in shares of ZIOPHARM Oncology by 7.5% during the second quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 1,673 shares in the last quarter. Amalgamated Bank boosted its position in shares of ZIOPHARM Oncology by 12.9% during the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,924 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of ZIOPHARM Oncology by 3.0% during the second quarter. Nationwide Fund Advisors now owns 72,799 shares of the biotechnology company’s stock worth $453,000 after purchasing an additional 2,127 shares in the last quarter. Legal & General Group Plc boosted its position in shares of ZIOPHARM Oncology by 6.3% during the second quarter. Legal & General Group Plc now owns 44,655 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 2,666 shares in the last quarter. Finally, Private Advisor Group LLC boosted its position in shares of ZIOPHARM Oncology by 10.6% during the second quarter. Private Advisor Group LLC now owns 45,949 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 4,408 shares in the last quarter. 40.23% of the stock is currently owned by institutional investors.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about ZIOPHARM Oncology? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ZIOPHARM Oncology and related companies.